FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection By Ogkologos - October 2, 2025 439 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study MK-3475A-D77 Source RELATED ARTICLESMORE FROM AUTHOR ESMO contributes to discussions on the future of cancer care at EU Cancer Mission event Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma MOST POPULAR Study Adds to Debate about Mammography in Older Women September 12, 2023 Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in... August 11, 2026 Ability of Deep Learning to Accurately Diagnose Frequent STS Subtypes from... August 26, 2021 ΝΕΑ ΓΙΑ ΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ December 27, 2018 Load more HOT NEWS Zooming in: Fine-tuning the picture to diagnose oesophageal cancer earlier Efficacy of Sunitinib in Patients with Metastatic Phaeochromocytomas and Paragangliomas Can Using Hair Dyes or Hair Relaxers Impact Your Cancer Risk? 21-Month-Old Girl Celebrates After Beating Stage 4 Cancer
